News|Articles|February 11, 2016

MPI Reasearch Invests in Upgrades and Department Expansions

MPI Research plans to renovate more than 55,000 square feet of facility space as part of the company’s plan to invest in upgrades and department expansion.

MPI Research, an early-stage drug development contract research organization (CRO) based in Michigan, is investing more than $5 million in a facility renovation to begin in 2016. The company plans to renovate more than 55,000 square feet of facility space.

Ed Amat, executive vice-president of global sales and marketing, says in a press announcement that the expansion reflects the increasing demand for investigational and preclinical pharmaceutical and medical device studies. Amat also says that MPI plans to renovate the company’s clinical pathology lab.

In the upcoming year, MPI hopes to increase the company’s workforce by approximately 10%. The company also plans to expand its surgical department with upgraded suites and additional equipment capabilities.

Source: MPI 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.